ReviewBioMed research international2015
The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years?
Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.The Cochrane database of systematic reviews · 2024Pooled it
- Trial
- Dual-modality breast cancer screening compared to MRI or mammography alone among female Hodgkin lymphoma survivors who received chest radiotherapy.Breast cancer research and treatment · 2026Article
- Prediction of breast cancer risk for adolescents and young adults with Hodgkin lymphoma.Journal of the National Cancer Institute · 2025Article
- Population based registry study on large B-cell lymphoma mortality and morbidity in Finland.Acta oncologica (Stockholm, Sweden) · 2025Article
- Immediate Breast Reconstruction Outcomes in Patients with Prior Mantle and Whole Breast Irradiation.Plastic and reconstructive surgery. Global open · 2024Article
- How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?Medicina (Kaunas, Lithuania) · 2024Review
- Review
- [Endocrine disorders after combined chemoradiotherapy in Hodgkin Lymphoma survivors].Problemy endokrinologii · 2023Article
- Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure.Current heart failure reports · 2023Review
- Pericardial Effusion during Proton Therapy in a Patient with Chemorefractory Hodgkin Lymphoma.International journal of particle therapy · 2022Article
- Incidence patterns and review of Hodgkin lymphoma in the Republic of Armenia.Ecancermedicalscience · 2021Article
- Treatment outcome after radiochemotherapy in anal cancer patients staged withClinical and translational radiation oncology · 2020Article
- Volume de-escalation in radiation therapy: state of the art and new perspectives.Journal of cancer research and clinical oncology · 2020Review
- Early-Onset Bilateral Severe Valvular Regurgitation After Mediastinal Radiotherapy in Hodgkin Lymphoma Survivors: Should We Screen Prior to 10 Years After Mediastinal Radiotherapy?Ochsner journal · 2019Article
- Radiation-associated epithelial-myoepithelial carcinoma among five secondary malignancies: A case report and review of literature.World journal of clinical oncology · 2018Article
- Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity.Seminars in radiation oncology · 2017Review
- Mediastinal radiotherapy and central vein catheters: a warning.Anaesthesia reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, Hodgkin's lymphoma (HL) has an excellent clinical outcome, with overall survival of approximately 90% in early stages of the disease. Based on young age of the majority of patients at the time of diagnosis and their long survival time, increased attention has been focused on long-term toxicity of therapy. While novel, directly targeting antitumor agents, with an excellent safety profile, have been developed for HL treatment, the role of radiotherapy is still debated. Radiotherapy may induce cardiovascular disease and impairment of thyroid or pulmonary function and, most importantly, may lead to development of secondary cancers. As a consequence, the current radiation therapy planning paradigm is mainly focused on a reduction of field size. As it was investigated in clinical trials regional therapy is as effective as extended field radiotherapy, but less toxic. Although chemotherapy is the mainstay of HL treatment, consolidative involved field radiation therapy is still considered to be the standard of care in both early and advanced stages. Recently, further field reduction has been investigated to further decrease the late radiation-induced toxicity. In this paper we describe the role and safety profile of radiotherapy in the past and present and hope for the novel techniques in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.